Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting
muscarinic antagonist [LAMA] plus a long-acting β2-agonist [LABA]) are available for the …

Background Both long‐acting beta 2‐agonists and inhaled corticosteroids have been
recommended in guidelines for the treatment of chronic obstructive pulmonary disease …

Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …

Chronic obstructive pulmonary disease (COPD) is a respiratory syndrome affecting more
than 80 million people worldwide and is estimated to become the third-leading cause of …

BACKGROUND: Evidence suggests that real-world treatment patterns of chronic obstructive
pulmonary disease (COPD) do not always follow evidence-based treatment …

A single inhaler containing inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA)/long-
acting muscarinic antagonist (LAMA) is a more convenient way of delivering triple therapy in …

Recent trials reported significant reductions in all-cause mortality with single-inhaler triple
therapy for chronic obstructive pulmonary disease (COPD). However, reviews of these trials …

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease,
characterized by persistent and progressive airflow limitation, worsening reduced exercise …

There is currently no consensus on the treatment sequence in chronic obstructive pulmonary
disease (COPD), although it is recognized that early diagnosis is of paramount importance …

The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …